GSK plc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while iShares 1 3 Year Treasury Bond ETF trades at $81.94. The key difference: GSK plc pays a 3.57% dividend while iShares 1 3 Year Treasury Bond ETF pays none, and GSK plc is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| GSK | SHY | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $83.18 |
52-Week Low | $38.22 | $81.77 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.92, up 0.08% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights institutional buying interest amid fluctuating Treasury yields driven by inflation data and geopolitical tensions.
The outlook for SHY is influenced by Federal Reserve policy expectations and inflation trends. Opportunities include its role as a short-duration bond haven during volatility, but risks involve rising yields pressuring prices and macroeconomic uncertainty. Investors should weigh interest rate sensitivity against current institutional accumulation.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →